Valuation: Gennex Laboratories Limited

Market Cap 2.13B 22.44M 20.05M 18.42M 16.73M 31.41M 32.2M 220M 88.43M 1.12B 84.23M 82.43M 3.56B P/E 2025
15.4x
P/E 2026 8.26x
Enterprise Value 2.55B 26.87M 24.01M 22.05M 20.03M 37.61M 38.55M 263M 106M 1.34B 101M 98.7M 4.26B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
66.61%
Yield 2025 *
-
Yield 2026 -
10-01 Gennex Laboratories Limited Announces Board Changes CI
08-14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
1 day+6.58%
1 week+1.86%
Current month+9.10%
1 month-10.71%
3 months-1.24%
6 months-12.41%
Current year-38.81%
1 week 7.7
Extreme 7.7
9.21
1 month 7.7
Extreme 7.7
10.25
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
16.3
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 17/05/2012
Director of Finance/CFO - 11/11/2024
Compliance Officer 62 19/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 20/12/2020
Director/Board Member 62 30/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%+1.86%-46.74%-21.31% 21.07M
-0.26%+9.71%+56.87%+147.69% 1,257B
-1.73%-1.05%+42.77%+75.71% 651B
-1.19%-0.38%+34.61%+101.75% 510B
-1.56%-2.01%+50.67%+64.81% 388B
-2.76%+1.33%+74.22%+39.01% 366B
-0.02%+2.11%+32.16%+57.79% 303B
-0.72%+7.32%+11.29%+33.98% 288B
-0.81%+2.96%+55.66%+70.91% 252B
-1.46%+5.90%+38.03%+106.47% 211B
Average -0.42%+3.69%+34.95%+67.68% 422.67B
Weighted average by Cap. -1.09%+5.30%+47.05%+93.20%

Financials

2025 2026
Net sales 1.38B 14.56M 13.01M 11.95M 10.85M 20.38M 20.89M 143M 57.37M 728M 54.64M 53.47M 2.31B 1.73B 18.24M 16.29M 14.96M 13.59M 25.52M 26.16M 179M 71.86M 912M 68.45M 66.98M 2.89B
Net income 181M 1.91M 1.71M 1.57M 1.43M 2.68M 2.74M 18.74M 7.54M 95.65M 7.18M 7.03M 303M 210M 2.21M 1.98M 1.82M 1.65M 3.1M 3.18M 21.69M 8.73M 111M 8.31M 8.13M 351M
Net Debt -275M -2.9M -2.59M -2.38M -2.16M -4.06M -4.16M -28.41M -11.43M -145M -10.89M -10.65M -460M 420M 4.43M 3.96M 3.63M 3.3M 6.2M 6.35M 43.38M 17.45M 221M 16.62M 16.27M 702M
Projected Income Statement - Annual - Gennex Laboratories Limited
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
125
Date Price Change Volume
03/11/26 ₹8.750 +6.58% 321,525
02/11/26 ₹8.210 +2.37% 1,053,207
30/10/26 ₹8.020 -10.49% 1,321,688
29/10/26 ₹8.960 -1.54% 188,622
28/10/26 ₹9.100 +2.48% 286,354
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock